Dr DeBernardo on the Role of PARP Inhibitors in Frontline Ovarian Cancer
Robert DeBernardo, MD, discusses the current role of PARP inhibitors in the frontline treatment landscape in ovarian cancer.
Robert Debernardo Lauraj Fogarty Uterine Cancer Research Department Of Gynecologic Oncology Peritoneal Surface Malignancy Program Gynecologic Oncology
Source: onclive.com